Preclinical/clinical evaluation of a CDK4/6 inhibitor + 5-FU in colon cancer

CDK4/6 抑制剂 5-FU 在结肠癌中的临床前/临床评价

• 批准号: 178342
• 负责人: Vickers Michael M
• 金额: $ 2.55万
• 依托单位: Ottawa Regional Cancer Centre
• 依托单位国家: 加拿大
• 项目类别: Fellowship Programs
• 财政年份: 2008
• 资助国家: 加拿大
• 起止时间: 2008-10-01 至 2009-10-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=178342&lang=en
• 关键词: Human Cancer Cell Lines; Medical Oncology; Novel Chemotherapy Agent; Overcoming Chemotherapy Resistance; Phase I Clinical Trial

5-Fluorouracil (5-FU) is a commonly used chemotherapy in Breast and Colon cancer. Unfortunately, it often stops working with time because cancer cells mutate and change the target for 5-FU. We are currently working with a new drug that helps undo this mut

5-氟尿嘧啶（5-FU）是乳腺癌和结肠癌常用的化疗药物。不幸的是，它经常随着时间的推移而停止工作，因为癌细胞突变并改变了5-FU的靶点。我们目前正在研究一种新的药物，有助于消除这种突变。